M Buti

Summary

Affiliation: Hospital Universitari Vall d'Hebron
Country: Spain

Publications

  1. ncbi Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C
    Maria Buti
    Liver Unit, Department of Internal Medicine, Hospital Valle Hebron and Ciberehd del Institut Carlos III, Barcelona, Spain Electronic address
    Gastroenterology 146:744-753.e3. 2014
  2. ncbi Preparing the patient for success: treat or wait?
    Maria Buti
    Liver Unit, Hospital Universitario Vall d Hebron, Barcelona, Spain Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Spain Electronic address
    Dig Liver Dis 45:S332-6. 2013
  3. doi Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review
    Maria Buti
    Servicio de Hepatologia, Hospital General Universitario Valle de Hebron, Paseo Valle de Hebron 119, 08035, Barcelona, Spain
    Pharmacoeconomics 31:63-75. 2013
  4. ncbi Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B
    Maria Buti
    CIBERehd, Instituto Carlos III, Madrid, Spain
    Expert Rev Gastroenterol Hepatol 6:413-21. 2012
  5. doi [Quantification of hepatitis B virus HBsAg: clinical implications]
    Maria Buti
    Servicio de Hepatologia, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Med Clin (Barc) 138:483-8. 2012
  6. doi Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients
    Maria Buti
    CIBER on Liver and Digestive Diseases, Hospital Vall d Hebron, corrected Barcelona, Spain
    Eur J Gastroenterol Hepatol 24:535-42. 2012
  7. doi [New agents for the treatment of hepatitis C]
    Maria Buti
    Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Instituto de Salud Carlos III, Espana
    Enferm Infecc Microbiol Clin 30:147-50. 2012
  8. pmc Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series
    Mònica Sabaté
    Fundacio Institut Catala de Farmacologia, Universitat Autonoma de Barcelona, Hospital Universitari Vall d Hebron, Barcelona, Spain
    BMC Gastroenterol 11:80. 2011
  9. ncbi Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients
    M Buti
    Liver Unit and Biochemistry Department, Hospital Universitario Vall d Hebron and CIBER EHD, Barcelona, Spain
    J Hepatol 47:366-72. 2007
  10. ncbi Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypes
    Maria Buti
    Liner Unit, Hospital General Universitari Pall d Hebron, Barcelona, Spain
    J Clin Virol 34:S79-82. 2005

Detail Information

Publications68

  1. ncbi Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C
    Maria Buti
    Liver Unit, Department of Internal Medicine, Hospital Valle Hebron and Ciberehd del Institut Carlos III, Barcelona, Spain Electronic address
    Gastroenterology 146:744-753.e3. 2014
    ..We performed an open-label, multicenter, phase 3 study of the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis...
  2. ncbi Preparing the patient for success: treat or wait?
    Maria Buti
    Liver Unit, Hospital Universitario Vall d Hebron, Barcelona, Spain Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Spain Electronic address
    Dig Liver Dis 45:S332-6. 2013
    ....
  3. doi Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review
    Maria Buti
    Servicio de Hepatologia, Hospital General Universitario Valle de Hebron, Paseo Valle de Hebron 119, 08035, Barcelona, Spain
    Pharmacoeconomics 31:63-75. 2013
    ..Chronic hepatitis B is a common, progressive disease, particularly when viral replication is detected. Oral antivirals can suppress viral replication and prevent or delay the development of cirrhosis and liver-related complications...
  4. ncbi Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B
    Maria Buti
    CIBERehd, Instituto Carlos III, Madrid, Spain
    Expert Rev Gastroenterol Hepatol 6:413-21. 2012
    ..In addition, studies including patients that have been previously treated with lamivudine or adefovir are discussed...
  5. doi [Quantification of hepatitis B virus HBsAg: clinical implications]
    Maria Buti
    Servicio de Hepatologia, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Med Clin (Barc) 138:483-8. 2012
    ..The role of the quantification of HBsAg in the treatment with nucleoside analogues is still not well understood and requires further studies...
  6. doi Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients
    Maria Buti
    CIBER on Liver and Digestive Diseases, Hospital Vall d Hebron, corrected Barcelona, Spain
    Eur J Gastroenterol Hepatol 24:535-42. 2012
    ..Entecavir is an effective treatment for chronic hepatitis B. However, data from clinical practice are limited, especially in hepatitis B e antigen (HBeAg)-positive patients...
  7. doi [New agents for the treatment of hepatitis C]
    Maria Buti
    Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBERehd, Instituto de Salud Carlos III, Espana
    Enferm Infecc Microbiol Clin 30:147-50. 2012
    ..Both increase rates of SVR in naïve and in previously treated patients with the advantage that in some cases therapy can be shortened. However, these drugs have new side effects such as a rash and an increase in the rate of anaemia...
  8. pmc Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series
    Mònica Sabaté
    Fundacio Institut Catala de Farmacologia, Universitat Autonoma de Barcelona, Hospital Universitari Vall d Hebron, Barcelona, Spain
    BMC Gastroenterol 11:80. 2011
    ..The aim is to describe the characteristics of patients admitted to hospital with jaundice who had previous exposure to therapeutic doses of paracetamol. An assessment of the causality role of paracetamol was performed in each case...
  9. ncbi Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients
    M Buti
    Liver Unit and Biochemistry Department, Hospital Universitario Vall d Hebron and CIBER EHD, Barcelona, Spain
    J Hepatol 47:366-72. 2007
    ..To determine the factors associated with virological response (VR), HBeAg loss or the emergence of adefovir (ADV)-related mutations in ADV-treated chronic hepatitis B (CHB) patients with lamivudine (LAM) resistance...
  10. ncbi Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypes
    Maria Buti
    Liner Unit, Hospital General Universitari Pall d Hebron, Barcelona, Spain
    J Clin Virol 34:S79-82. 2005
    ..Analyses of both naturally occurring viral variants and in vitro mutagenesis studies have identified some mutations that have a role in viral latency, pathogenesis of liver disease, immune escape, and resistance to antiviral therapy...
  11. ncbi Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B
    M Buti
    Department of Hepatology, Hospital Vall d Hebron, Barcelona, Spain
    Aliment Pharmacol Ther 23:409-19. 2006
    ..To estimate the cost-effectiveness over a 4-year duration of lamivudine and adefovir dipivoxil for patients with hepatitis B 'e' antigen-negative chronic hepatitis B...
  12. ncbi Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patients
    Maria Buti
    Liver Unit, Hospital General Universitario Valle de Hebron, Paseo Valle hebron 117, Barcelona 08035, Spain
    J Hepatol 44:S60-4. 2006
    ..Currently, the literature does not provide adequate information on the effect of HCV infection on the quality of life of HIV-HCV co-infected patients or the most cost-effective HCV therapy...
  13. ncbi Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1
    Maria Buti
    Department of Hepatology, Hospital Vall d Hebron, Barcelona, Spain
    Pharmacoeconomics 23:1043-55. 2005
    ..The monitoring of early virological response (EVR) is therefore an important tool for quickly identifying non-responders, permitting therapy discontinuation and avoiding adverse effects and costs...
  14. ncbi Evaluating the cost of sustained virologic response in naïve chronic hepatitis C patients treated à la carte
    M Buti
    Department of Hepatology, Hospital Vall d Hebron, and CiBER de Enfermedades Hepaticas y Digestivas del Instituto de Salud Carlos III, Barcelona, Spain
    Aliment Pharmacol Ther 26:705-16. 2007
    ..There is a tendency to individualize treatment in chronic hepatitis C patients depending on viral load and rapid clearance of HCV-RNA...
  15. ncbi Hepatitis B and C virus resistance to antiviral therapies--EASL-AASLD-APASL-ALEH-IASL conference
    Maria Buti
    Hospital Vall d Hebron CIBER EHD, Liver Unit, Paseo Valle de Hebron 119, Barcelona 0803, Spain
    IDrugs 11:239-41. 2008
  16. ncbi [Telbivudine in the treatment of the chronic B hepatitis]
    María Asunción Butí
    Servicio de Hepatologia, Hospital General Universitario Vall d Hebron, Barcelona, Spain
    Gastroenterol Hepatol 31:258-63. 2008
  17. ncbi [Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B]
    Maria Buti
    Servicio de Hepatología y Medicina Interna, Hospital General Universitario Vall d Hebron, CIBER del Instituto de Salud Carlos II, Barcelona, Espana
    Enferm Infecc Microbiol Clin 26:32-8. 2008
    ..In cases of resistance to one of these drugs, combined treatment is advised...
  18. ncbi [Therapy of chronic hepatitis B]
    Maria Buti
    Hospital General Universitario Vall d Hebrón de Barcelona, Barcelona, Espana
    Acta Gastroenterol Latinoam 38:291-7. 2008
    ..The challenge are to prevent the emergence of HBV drug resistance and to achieve complete and persistent HBV replication in order to avoid the progression of the liver disease and the development of HBV related complications...
  19. doi Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B
    Maria Buti
    Servicio de Hepatologi a, Hospital Vall d Hebrón and Ciber ehd del Instituto Carlos III, Barcelona, Spain
    J Hepatol 51:640-6. 2009
    ..The aim of this study was to estimate the cost-effectiveness of the oral antiviral treatments lamivudine, adefovir, telbivudine, entecavir and tenofovir, in patients with CHB...
  20. doi Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study
    M Buti
    CIBERehd, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion, Barcelona, Spain
    J Viral Hepat 18:434-42. 2011
    ..Currently, patients with chronic HDV disease are older, and factors associated with worse prognosis include the presence of cirrhosis and age at the time of diagnosis...
  21. doi Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response
    Maria Buti
    Liver Unit, Valle d Hebron Ciberehd University Hospital, and Biomedical Research Center Network in the Area of Hepatic and Digestive Disorders of the Carlos III Health Institute, Barcelona, Spain
    Hepatology 52:1201-7. 2010
    ..5% of slow responders treated for 48 weeks and 8.2% of those treated for 72 weeks. Among slow responders with a <2-log drop in HCV RNA at week 8, SVR was 39% in the 72-week arm and 19% in the 48-week arm...
  22. ncbi Drugs in development for hepatitis B
    Maria Buti
    Liver Unit, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    Drugs 65:1451-60. 2005
    ....
  23. ncbi Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C
    Maria Buti
    Department of Hepatology, Hospital Vall d Hebron, Barcelona, Spain
    J Hepatol 42:639-45. 2005
    ..Our aim was to estimate the future morbidity, mortality and costs of chronic HCV infection in a cohort of patients infected by HCV and to evaluate the impact of HCV therapy...
  24. ncbi [Current and future applications of viral clearance kinetics in the treatment of hepatitis C]
    M Buti
    Servicio de Hepatología Medicina Interna, Hospital General Universitari Vall d Hebron, Paseo Vall d Hebron, 119, 08035 Barcelona, Espana
    Gastroenterol Hepatol 27:24-9. 2004
  25. doi 1990-2010: two decades of interferon-based therapy
    Maria Buti
    Liver Unit, Hospital General, Universitario Valle Hebron, Paseo Valle Hebron 119, Barcelona 08035, Spain
    Clin Liver Dis 15:473-82. 2011
    ..Even with the development of new protease inhibitors, it is likely that interferon will remain an essential component of hepatitis C treatment...
  26. ncbi Sporadic cases of acute autochthonous hepatitis E in Spain
    Maria Buti
    Liver Unit, Hospital General Universitario Valle Hebron, Paseo Valle de Hebron 119, 08035 Barcelona, Spain
    J Hepatol 41:126-31. 2004
    ..In industrialized countries hepatitis E virus (HEV) infection is rare and its diagnosis is difficult because the utility of available tests is not well established...
  27. ncbi Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin
    Maria Buti
    Servicio de Hepatologia, Hospital General Universitario Valle de Hebron, Barcelona, Spain
    J Hepatol 40:527-32. 2004
    ..We examined the usefulness of measuring total HCV Core Ag in early treatment with peginterferon alpha-2b and ribavirin in genotype 1 patients in the prediction of response and compared the results with those from HCV RNA quantification...
  28. ncbi Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference
    R Jardi
    Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Hepatology 34:404-10. 2001
    ..The reciprocal inhibition of viral replication seemed to be little influenced by the inherent genomic factors studied...
  29. ncbi Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B
    M Buti
    Unidad de Hepatologia, Hospital General Universitario Valle de Hebron, Paseo Valle Hebron s n, Barcelona 08035, Spain
    J Infect Dis 183:1277-80. 2001
    ..Therefore, quantitative HBV DNA testing is very useful in deciding whether to continue therapy, because of the low likelihood of response in patients who remain HBV DNA positive at month 3 of treatment...
  30. ncbi Hepatitis B virus genotypes and G1896A precore mutation in 486 Spanish patients with acute and chronic HBV infection
    F Rodriguez-Frias
    Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
    J Viral Hepat 13:343-50. 2006
    ..The unequal prevalence of genotypes between acute and chronic infection suggests that genotype A is associated with a higher tendency to cause chronic infection...
  31. ncbi Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients
    R Jardi
    Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
    J Viral Hepat 14:835-40. 2007
    ..This fact, as well as the emergence of ETV-resistant variants during lamivudine treatment, should be kept in mind when selecting candidates for ETV therapy...
  32. ncbi Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants
    R Jardi
    Department of Biochemistry, Hospital Universitario Valle Hebron, Paseo Valle Hebron s n, Barcelona, Spain
    J Virol Methods 83:181-7. 1999
    ..Since it is a rapid low-cost technique, PCR- RFLP is suitable for large-scale screening of these polymorphisms in clinical samples...
  33. ncbi Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C
    M Buti
    Department of Hepatology, Hospital Vall d Hebron, Barcelona, Spain
    J Hepatol 33:651-8. 2000
    ..The objective of this study was to determine if the incremental sustained response rate of combination therapy is sufficient to outweigh its extra cost...
  34. ncbi Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus
    R Barcena
    Hospital Ramon y Cajal, Madrid, Spain
    Transplant Proc 37:3960-2. 2005
    ....
  35. ncbi Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B
    M Buti
    Unidad de Hepatologia, Hospital General Universitario Valle de Hebron, Barcelona, Spain; Glaxo Wellcome, Madrid, Spain
    J Viral Hepat 8:270-5. 2001
    ..However, its efficacy tends to decrease overtime and it is associated with an increase in YMDD variants, even in some cases, of complete response...
  36. ncbi Quantitative detection of hepatitis B virus DNA in serum by a new rapid real-time fluorescence PCR assay
    R Jardi
    Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
    J Viral Hepat 8:465-71. 2001
    ..The assay is automatic except for DNA extraction and the running time is only 70 min. The LightCycler real-time PCR is useful for identifying different states of HBV infection and for evaluating the efficacy of viral therapy...
  37. ncbi A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C
    M Buti
    Department of Hepatology, Hospital Vall d Hebron, Barcelona, Spain
    Aliment Pharmacol Ther 17:687-94. 2003
    ..To estimate the cost-effectiveness of therapy and analyse the effect of therapy compliance in naive patients with chronic hepatitis C...
  38. doi Main mutations in the hepatitis B virus basic core promoter (A1762T/G1764A) before HBeAg loss are markers that identify patients who will require long-term treatment
    D Tabernero
    Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain
    Aliment Pharmacol Ther 32:97-104. 2010
    ..Some patients continue to have detectable HBV-DNA levels with liver disease progression after hepatitis B e antigen (HBeAg) loss. It is important to identify these patients, candidates for long-term treatment...
  39. ncbi Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapy
    M Buti
    Liver Unit, Servicio de Hepatologia, Hospital General Universitario Valle de Hebron, Barcelona, Spain
    Aliment Pharmacol Ther 21:1349-56. 2005
    ..Lamivudine therapy for chronic hepatitis B has been associated with changes in different regions of the hepatitis B virus nucleotide sequence...
  40. ncbi HIV, HEV and cirrhosis: evidence of a possible link from eastern Spain
    R Jardi
    Department of Biochemistry, Vall d Hebron Hospital, University Autonoma of Barcelona, Barcelona, Spain
    HIV Med 13:379-83. 2012
    ..The aim of the study was to assess the seroprevalence of hepatitis E virus (HEV) infection in an HIV-infected population, as determined by HEV immunoglobulin G (IgG) antibodies (anti-HEV)...
  41. ncbi High-Dose interferon-alpha2b plus ribavirin for retreatment of interferon-nonresponsive patients infected with genotype 1 hepatitis C virus
    M Buti
    Liver Unit, Hospital General Universitari Vall d'Hebron, Barcelona, Spain
    Dig Dis Sci 46:2396-400. 2001
    ..Retreatment with an initial high-dose IFN-alpha2b plus ribavirin significantly reduces viral load in genotype 1-infected, interferon-nonresponsive patients...
  42. ncbi Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients
    M Crespo
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Viral Hepat 14:228-38. 2007
    ..Frequent monitoring of virological response may be very helpful to optimize treatment compliance, to tailor treatment duration and to minimize side effects...
  43. doi Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D
    Melanie Schaper
    Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona 08035, Spain
    J Hepatol 52:658-64. 2010
    ..This study presents a real-time reverse-transcription PCR (rt-RT-PCR) assay for hepatitis delta virus (HDV) RNA quantification, designed to clarify the interplay between HDV and hepatitis B virus (HBV) in chronic infection...
  44. ncbi Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues
    Francisco Rodriguez-Frias
    Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
    J Med Virol 79:1671-3. 2007
    ..Despite the presence of these variants, the patient has had a complete virological response...
  45. ncbi Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin
    Maria Buti
    Liver Unit, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    Hepatology 35:930-6. 2002
    ..Higher doses of peginterferon alfa-2b also accelerate viral clearance...
  46. doi Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?
    M Simón-Talero
    Liver Unit, Hospital Universitari Vall d Hebron, Department of Medicine, Universitat Autonoma de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Barcelona, Spain
    J Viral Hepat 19:14-7. 2012
    ..The adverse events related to ribavirin and drug-drug interactions during therapy for hepatitis C are discussed...
  47. ncbi [Study of HLA-II antigens in chronic hepatitis C and B and in acute hepatitis B]
    M Cotrina
    Servicio de Hepatologia, Hospital General Universitario Vall d Hebron, Barcelona
    Gastroenterol Hepatol 20:115-8. 1997
    ..The use of PCR techniques which discriminate between the different alleles of the HLA antigens may provide better knowledge of the immune response...
  48. doi Current trends in chronic hepatitis B management: results of a questionnaire
    Iñigo Les
    Liver Unit, Hospital General Universitario Vall d Hebron and CIBER EHD, Barcelona, Spain
    Eur J Gastroenterol Hepatol 21:1177-83. 2009
    ..Aim of this study was to analyze general knowledge, therapeutic and diagnostic trends of physicians treating CHB in Spain...
  49. ncbi [Adefovir dipivoxil compassionate use program in Spain: efficacy and resistance analysis]
    Maria Buti
    Servicio de Hepatologia, Hospital Universitari Vall d Hebron, Barcelona, Espana
    Med Clin (Barc) 129:566-70. 2007
    ..The aim of this study was to evaluate the efficacy, safety and resistance of adefovir dipivoxil in patients with chronic hepatitis B refractory to treatment with lamivudine...
  50. ncbi Mutations in the basic core promoter region of hepatitis B virus. Relationship with precore variants and HBV genotypes in a Spanish population of HBV carriers
    Rosendo Jardi
    Department of Biochemistry, Hospital Universitario Vall d Hebron, Paseo Vall d Hebron 119 129, Barcelona 08035, Spain
    J Hepatol 40:507-14. 2004
    ..To determine the prevalence and significance of hepatitis B virus (HBV) basic core promoter (BCP) mutations and to establish their relationship with precore (preC) mutations, HBV genotypes and HBV-DNA levels...
  51. ncbi Current therapies for chronic hepatitis B
    Maria Buti
    Liver Unit, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    Ann Hepatol 2:108-12. 2003
  52. pmc Simultaneous quantification and genotyping of hepatitis B virus for genotypes A to G by real-time PCR and two-step melting curve analysis
    Wen Chun Liu
    Institute of Basic Medical Sciences, Department of Medicine, National Cheng Kung University, Tainan City 704, Taiwan, Republic of China, and Liver Unit, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    J Clin Microbiol 44:4491-7. 2006
    ..3% of 441 samples were accurately genotyped by the current assay. The method should be useful for genotyping and quantification of HBV DNA in areas where all genotypes exist...
  53. ncbi Usefulness of dried blood samples for quantification and molecular characterization of HBV-DNA
    Rosendo Jardi
    Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Hepatology 40:133-9. 2004
    ..In conclusion, the DBS sample is useful for HBV DNA quantification, genotyping, and detection of precore mutant and YMDD variants. All four determinations can be completed with a single drop of dried blood...
  54. ncbi Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients
    Manuel Crespo
    Infectious Diseases Department, Spain
    AIDS 21:477-81. 2007
    ..To investigate the utility of a week-4 virological response for sustained response prediction in hepatitis C virus (HCV) genotype 3/HIV-co-infected patients treated with interferon and ribavirin for 24 weeks...
  55. doi Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab
    Mayra J Sanchez
    Hospital Vall d Hebron, Liver Unit, CIBERehd Institute Carlos III, Paseo de Vall d Hebron, 08035 Barcelona, Spain
    J Hepatol 51:1091-6. 2009
    ..Patients with severe reactivation often have a fatal outcome despite treatment with lamivudine. The use of entecavir has not been reported in patients with severe HBV reactivation...
  56. ncbi Entecavir, FTC, L-FMAU, LdT and others
    Maria Buti
    Liver Unit, Hospital General Universitari Vall d Hebron, Paseo Valle de Hebron 119, Barcelona 08035, Spain
    J Hepatol 39:S139-42. 2003
    ..Currently, the drugs most likely to fulfill these criteria are the nucleoside analogs...
  57. pmc Prevalence of hepatitis E virus infection in children in the northeast of Spain
    Maria Buti
    Liver Unit, Biochemistry Departament, Hospital Universitario Valle Hebron and CIBER EHD of Instituto Carlos III, Passeig Vall d Hebron 119 121, 08035 Barcelona, Spain
    Clin Vaccine Immunol 15:732-4. 2008
    ..IgG anti-HEV antibodies were detected in 57 (4.6%) of the 1,249 samples analyzed, suggesting that some children are exposed to HEV in early childhood...
  58. pmc Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapy
    Rosendo Jardi
    Departments of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
    J Clin Microbiol 47:485-8. 2009
    ..The INNO-LiPA DR assay is a highly sensitive assay that is easily applicable for the detection and monitoring of entecavir resistance-conferring mutations and is more sensitive than sequencing for the detection of mixed sequences...
  59. ncbi Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response
    Francisco Rodriguez-Frias
    Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Antivir Ther 13:991-9. 2008
    ..Virological characteristics useful for predicting response have not been clearly elucidated. We determined pretreatment virological markers to predict non-response and possible emergence of new variants during therapy...
  60. ncbi Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy
    Rosendo Jardi
    Department of Biochemistry, Hospital General Universitario Vall d Hebron, Paseo Valle Hebron s n, Servicio de Bioquimica, Barcelona 08035, Spain
    J Hepatol 49:695-701. 2008
    ..The frequency of mixed hepatitis B virus (HBV) genotypes in chronic HBV (CHB) and genotype changes during natural disease evolution and as a result of antiviral therapy were investigated...
  61. ncbi De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection
    Jose L Tovar
    Servicio de Nefrologia, Hospital General Universitario Valle de Hebron, Barcelona 08035, Spain
    Int Urol Nephrol 40:539-41. 2008
    ..The patient exhibited a total remission when the antiviral treatment was discontinued...
  62. pmc Community-based seroepidemiological survey of hepatitis E virus infection in Catalonia, Spain
    Maria Buti
    Liver Service, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Vaccine Immunol 13:1328-32. 2006
    ..68; 95% CI, 1.03 to 2.70). In conclusion, anti-HEV antibodies were detected in 7.3% of the Catalan population. The seroprevalence of anti-HEV antibodies increased with age and was associated with previous minor surgery...
  63. ncbi Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence
    Maria Buti
    Hospital General Valle de Hebrón and CIBER EHD, Barcelona, Spain
    Transplantation 84:650-4. 2007
    ..Patients who adhere to long-term prophylaxis with lamivudine after early withdrawal of HBIg have a low risk of HBV recurrence, similar to those who receive combination prophylaxis...
  64. ncbi Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation
    Lluis Castells
    Liver Unit, Department of Biochemestry, Hospital General Vall d Hebron, Universitat Autonoma Barcelona, Barcelona, Spain
    Liver Transpl 8:892-900. 2002
    ....
  65. ncbi [Patient information. Prophylaxis in hepatitis B virus]
    M Buti
    Servicio de Hepatologia, Medicina Interna, Hospital General Universitari Vall d Hebron, Barcelona
    Rev Esp Enferm Dig 96:515. 2004
  66. ncbi Risk of acute liver injury associated with the use of drugs: a multicentre population survey
    M Sabate
    Fundacio Institut Catala de Farmacologia, Universitat Autonoma de Barcelona, Hospital Vall d Hebron, Barcelona, Spain
    Aliment Pharmacol Ther 25:1401-9. 2007
    ..Acute liver injury of uncertain aetiology is often drug related and quantitative information about the associated risk is scarce...
  67. pmc Hepatitis E virus epidemiology in industrialized countries
    Pilar Clemente-Casares
    University of Barcelona, Barcelona, Spain
    Emerg Infect Dis 9:448-54. 2003
    ..Our results suggest that HEV may be more prevalent than previously considered in industrialized countries and that variants of the virus circulate simultaneously in one region...
  68. doi Analysis of the evolution in the circulation of HAV and HEV in eastern Spain by testing urban sewage samples
    Jesus Rodriguez-Manzano
    Department of Microbiology, Faculty of Biology, University of Barcelona, Avd Diagonal 645, 08028, Barcelona, Spain
    J Water Health 8:346-54. 2010
    ..However, these improvements would not have an equivalent effect on the circulation of HEV and this observation could be explained by the presence of animal reservoirs for HEV, which act as external sources of infections...